RNAIII-inhibiting peptide(TFA),99.75%

产品编号:Bellancom-P1452A| 分子式:C47H57F3N10O13| 分子量:1027.01

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-P1452A
2100.00 杭州 北京(现货)
Bellancom-P1452A
6300.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

RNAIII-inhibiting peptide(TFA)

产品介绍 RNAIII-inhibiting peptide(TFA) 是一种有效的 Staphylococcus aureus 多肽抑制剂,在蜂窝组织炎、角膜炎、化脓性关节炎、骨肌炎和乳腺炎等疾病中有功效。
生物活性

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.

体外研究

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus. RNAIII-inhibiting peptide (RIP) inhibits the synthesis of both RNAII and RNAIII, while RAP activates in wild type S. aureus cells. RNAIII-inhibiting peptide (5 μg/106 cells) potently reduces bacterial cell adhesion to HEp2 cells in the absence of serum, but with slight overall reduction the presence of serum. RNAIII-inhibiting peptide inhibits while RAP induces the phosphorylation of TRAP.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

RNAIII-inhibiting peptide (20 mg/kg, i.v.) decreases lethality in mice challenged with S. aureus ATCC 25923, with the lethality rate of 70%, and when combined with cefazolin, imipenem, vancomycin, the rates are 20%, 15% and 10%. RNAIII-inhibiting peptide (20 mg/kg, i.v.) also causes decreased lethality in mice challenged with S. aureus Smith, with the lethality rate of 75%, and the lethality rate decreases to 30%, 10% and 10% when combined with cefazolin, imipenem, vancomycin.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

RNAIII-inhibiting peptide (20 mg/kg, i.v.) decreases lethality in mice challenged with S. aureus ATCC 25923, with the lethality rate of 70%, and when combined with cefazolin, imipenem, vancomycin, the rates are 20%, 15% and 10%. RNAIII-inhibiting peptide (20 mg/kg, i.v.) also causes decreased lethality in mice challenged with S. aureus Smith, with the lethality rate of 75%, and the lethality rate decreases to 30%, 10% and 10% when combined with cefazolin, imipenem, vancomycin.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状Solid
溶解性数据
In Vitro: 

DMSO : ≥ 150 mg/mL (146.06 mM)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9737 mL 4.8685 mL 9.7370 mL
5 mM 0.1947 mL 0.9737 mL 1.9474 mL
10 mM 0.0974 mL 0.4869 mL 0.9737 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服